Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tacere Reacquires Asian Rights to Novel Hepatitis C Treatment

publication date: Feb 4, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tacere Therapeutics of California said it reacquired Asian rights to its RNA interference candidates for hepatitis C infection from Oncolys BioPharma in Japan. Tacere announced the move immediately after Pfizer exercised its option to continue R&D of the company’s RNAi hepatitis drugs for ex-Asian markets. More details....

Stock Symbol: (NYSE: PFE)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners